Novartis Bets $2.9B on PTC Therapeutics' Huntington’s Disease Drug Breakthrough... and more - Life Science Headlines December 5, 2024

Novartis Bets $2.9B on PTC Therapeutics' Huntington’s Disease Drug Breakthrough Warren, NJ, December 2, 2024 (Reuters) -- Novartis is acquiring PTC Therapeutics' Huntington’s disease drug, PTC518, for up to $2.9 billion.  

Velentium Appoints Matt Hanks as CEO, Co-Founder Dan Purvis Named Board Chair to Propel Growth Houston, TX, December 2, 2024 (Business Wire) -- Velentium has announced a leadership transition to support its continued growth, appointing Matt Hanks as CEO and elevating Co-Founder Dan Purvis to Board Chair. 

Coherus Divests UDENYCA Franchise to Intas in $558.4M Deal to Fund Immuno-Oncology Expansion Redwood City, CA, December 3, 2024 (Globe Newswire) -- Coherus is selling its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million, using proceeds to repay debt and focus on its immuno-oncology portfolio. 

BioFuse Medical Technologies Appoints Rick Early as CEO Tampa, FL, December 4, 2024 (AccessWire) -- BioFuse Medical Technologies has announced significant leadership updates, appointing Rick Earley as its new CEO. 

COUR Pharmaceuticals Secures $40M Upfront in Genentech Deal, Potential Milestones Exceed $900M Chicago, December 3, 2024 (Globe Newswire) -- COUR Pharmaceuticals and Genentech have partnered to develop novel autoimmune disease treatments using COUR's tolerogenic nanoparticle platform. 

About the Author: Cari Kraft is the CEO of Jacobs Management Group, an Advisory Board Member at Experts OnTap, and the Publisher of Healthcare Sales and Marketing Magazine. Cari and her team specialize in placing top talent with Medical Device, Biotechnology, and Pharmaceutical companies nationwide.